Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma

Cancer Research

Volumn 62, Issue 13, 2002, Pages 3698-3701

  Schagdarsurengin, Undraga ^a   Gimm, Oliver ^a   Hoang Vu, Cuong ^a   Dralle, Henning ^a   Pfeifer, Gerd P ^b   Dammann, Reinhard ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; GENE PRODUCT; PROTEIN P16; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; UNCLASSIFIED DRUG;

ARTICLE; CANCER CLASSIFICATION; CELL CYCLE; CHROMOSOME 3P; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE ISOLATION; GENE LOCATION; GENE LOCUS; GENE SILENCING; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; METHYLATION; P16 GENE; PRIORITY JOURNAL; PROMOTER REGION; RASSF1A GENE; SOLID TUMOR; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TRANSCRIPTION REGULATION; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE;

CARCINOMA; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HELA CELLS; HUMANS; NEOPLASM PROTEINS; PROMOTER REGIONS (GENETICS); THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 0036644895     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Thyroid cancer
2. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis
3. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease
4. Genetic events in tumour initiation and progression in multiple endocrine neoplasia type 2
5. Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes
6. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3
7. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: Identification and evaluation of the resident candidate tumor suppressor genes
8. Hypermethylation of the CpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers
9. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours
10. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression
11. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma
12. Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas
13. Substrate specificities and identification of putative substrates of ATM kinase family members
14. High sensitivity mapping of methylated cytosines
15. Methyllation-specific PCR: A novel PCR assay for methylation status of CpG islands
16. Cellular differentiation, cytidine analogs and DNA methylation
17. A gene hypermethylation profile of human cancer
18. Cancer epigenetics comes of age
19. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis
20. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1
21. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p151NK4b and p161NK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas